Mechanisms downstream of reverse transcription reduce serum levels of HBV DNA but not of HBsAg in chronic hepatitis B virus infection by unknown
RESEARCH Open Access
Mechanisms downstream of reverse
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B virus infection
Simon B. Larsson*, Sebastian Malmström, Charles Hannoun, Gunnar Norkrans and Magnus Lindh
Abstract
Background: Hepatitis B virus (HBV) DNA in serum of chronically infected patients declines by 3–4 log10 units at
loss of HBe antigen (HBeAg) from serum. The mechanisms behind this decline, and the much smaller decline of
surface antigen (HBsAg) levels, are still not well known. The aim of this study was to get a better understanding of
this process by analysing both serum and intrahepatic markers of HBV replication.
Methods: Levels of HBV DNA and HBsAg in serum, and covalently closed circular DNA (cccDNA), pregenomic RNA
(pgRNA) and S-RNA and total intrahepatic HBV DNA (ihDNA) in liver biopsies from 84 chronically infected patients
(16 positive and 68 negative for HBeAg) were analysed.
Results: Lower HBV DNA levels within HBeAg-positive stage reflected lower levels of cccDNA and pgRNA with
strong correlation. In HBeAg-negative patients, ihDNA levels were greater and HBV DNA levels in serum lower than
expected from pgRNA levels. A lower HBV DNA/HBsAg ratio corresponded with lower pgRNA/cccDNA (p < 0.01)
and higher S-RNA/cccDNA (p < 0.0001) ratios, suggesting that in HBeAg-negative patients transcription of pgRNA,
but not of S-RNA, becomes suppressed.
Conclusions: The marked reduction of HBV DNA in serum after loss of HBeAg appears to be due to combined
reduction of cccDNA, pgRNA and yet unidentified mechanisms downstream of reverse transcription. Such mechanisms
include faster clearance of circulating virus or blocked secretion of virions, the latter supported by the observed relative
increase of ihDNA in HBeAg-negative patients. The smaller reduction of S-RNA than of pgRNA partly explains why
HBsAg remain high in the HBeAg-negative stage, supporting the possibility of HBsAg synthesis from integrated
HBV DNA.
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Background
Despite the availability of an effective vaccine, chronic
hepatitis B virus (HBV) infection remains an important
cause of liver cirrhosis and hepatocellular carcinoma, in
particular in East Asia and Sub-Saharan Africa [1]. In
clinical diagnostics, HBV DNA levels in serum are the
most important marker for the assessment of prognosis
and treatment outcome during chronic HBV infection.
In early stage of chronic infection HBV DNA usually
persists at high levels, above 7–8 log10 IU/mL, for many
years, often decades. Later in life the HBV DNA levels
decline when the immune response evolves to more effi-
ciently suppress viral replication. The greatest reduction
of HBV DNA is observed at loss of hepatitis B e antigen
(HBeAg) from the blood, a critical step that typically
represents a transition from high to low replicative stage,
usually also conferring clinical improvement [2]. Mecha-
nisms that explain this pronounced reduction of viremia
are not fully clarified. Part of the reduction of HBV
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DNA in serum is a result of reduced intrahepatic levels
of covalently closed circular DNA (cccDNA), and of
the pregenomic RNA (pgRNA), a transcript from cccDNA
that is reverse transcribed to minus strand HBV DNA
during formation of new viral particles [3]. The cccDNA
minichromosome is also template for transcripts that are
translated into hepatitis B surface antigens (HBsAg) em-
bedded in the envelope of both virions and so-called sub-
viral particles (SVP), of which the latter are produced in
great excess [4].
In diagnostics, detection of HBsAg has been used as
the basic test for identification of HBV infection for de-
cades. Recently, quantification of HBsAg has come into
focus as a complement to HBV DNA levels for monitor-
ing both the natural course of infection and the response
to treatment [5]. Levels of HBsAg, which mainly repre-
sent the levels of SVP [4], are more stable over time than
HBV DNA, with a much smaller decline during the
course of infection. This difference is in particular strik-
ing during loss of HBeAg when HBV DNA declines by
3–4 log10 or even more, whereas the HBsAg levels often
are reduced by only 1 log10 [6–8]. As a consequence, the
ratio between these two serum markers (HBV DNA/
HBsAg) decreases when HBV DNA reaches very low or
even undetectable levels while HBsAg remains at signifi-
cant levels [9]. Previous studies indeed indicate that re-
duced transcription of pgRNA from cccDNA may
contribute to the decline in HBV DNA [10]. It is how-
ever not well known to what extent such effects are spe-
cific for pgRNA, i.e. are not also reducing S-RNA. In the
present study we explored the relations between HBV
markers in serum and liver biopsies from both HBeAg-
positive and HBeAg-negative patients, searching for ex-
planations to the strong reduction of HBV DNA in
serum and the shift in HBV DNA/HBsAg ratio that
occur in parallel with loss of HBeAg. The contribution
of different steps of replication to the reduced serum
levels of HBV DNA and HBsAg is discussed.
Results
Patient characteristics
A summary of patient characteristics is found in Table 1.
HBeAg-negative patients had significantly lower levels of
viral markers than HBeAg-positive patients except for a
higher ratio of S-RNA to cccDNA.
Reduction of viral replication prior to loss of HBeAg
In order to study this, the levels of HBV markers within
HBeAg-positive patients, and correlations between them,
were analysed. As shown in Fig. 1a, the levels of
cccDNA spanned over more than 2 log10 units within
this group. Levels of pgRNA correlated well with
cccDNA (R2 = 0.88), with a regression line slope of 1.33,
indicating that a 2 log10 decline of cccDNA
corresponded to a 2.7 log10 decline of pgRNA. The cor-
relations in Fig. 1b (ihDNA and pgRNA) and C (serum
HBV DNA and ihDNA) were also strong among
HBeAg-positive patients, with R2 = 0.88 and R2 = 0.77.
The slopes were however different, indicating that
ihDNA declines less than pgRNA (k = 0.56), whereas
HBV DNA in serum declines more than ihDNA (k =
1.96). As a result, the correlation between pgRNA and
HBV DNA in serum had k = 1.04 (R2 = 0.62), indicating
that until loss of HBeAg, reduction of HBV DNA in
serum is achieved mainly by mechanisms that lead to re-
duced pgRNA levels (Fig. 1d).
Viral markers after loss of HBeAg
To some extent this can be studied by analysing correlations
between viral markers within HBeAg-negative patients.
Figure 2a shows that the correlation between cccDNA
and pgRNA was poorer (R2 = 0.36) than in HBeAg-
positive stage, indicating that the regulation of pgRNA
levels becomes more variable after loss of HBeAg. By
contrast, the correlation between pgRNA and ihDNA
(Fig. 2b) remained strong and with a similar slope in
HBeAg-negative (R2 = 0.72, k = 0.50) as in HBeAg-positive
patients, suggesting that the rate of reverse transcription
is unaltered after loss of HBeAg. The correlation between
ihDNA and serum HBV DNA was on the other hand re-
markably different in HBeAg-negative patients (Fig. 2c)
with low R2 (0.14). In particular, the levels of HBV DNA
in serum were much lower in a large proportion of pa-
tients than one would expect from the pgRNA and
ihDNA level (if the correlations had been the same as
in HBeAg-positive stage), suggesting that viremia is







Age, years, median, (range) 27 (16–60) 34 (18–59) 0.02
Gender (M/F) 11/5 40/28 0.57
Genotype (A/B/C/D) 3/4/2/7 15/7/3/43 –
Serum HBV DNAa 8.30 ± 0.38 4.30 ± 0.14 <0.0001
Serum HBsAgb 4.40 ± 0.18 3.41 ± 0.11 <0.0001
HBV DNA/HBsAg 3.90 ± 0.29 0.89 ± 0.14 <0.0001
ALT/ULN, median, (range) 1.37 (0.68–8.6) 0.72 (0.24–12.38) <0.001
cccDNAc −0.70 ± 0.20 −2.67 ± 0.10 <0.0001
S RNAc/cccDNAc 1.65 ± 0.20 2.73 ± 0.11 <0.0001
pgRNAc/cccDNAc 2.04 ± 0.12 1.50 ± 0.11 <0.01
pgRNAc/S RNAc 0.39 ± 0.23 −1.22 ± 0.07 <0.0001
Virological values as mean ± SEM. P values by Mann-Whitney U test for age
and ALT, t test for virological parameters and Fisher’s exact test for gender
alog10 cp/mL
blog10 IU/mL
clog10 copies/cEq (cell equivalent), ALT/Upper Limit of Normal
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supressed by mechanisms acting after reverse tran-
scription or after secretion into the blood.
Comparisons of viral markers at group level (HBeAg-
positive vs. negative) revealed differences due to combined
effects before and after loss of HBeAg, and are shown by
box plots in Fig. 3a. Thus, the mean (median) cccDNA
levels were 1.97 (2.27) log10 lower, pgRNA levels 2.52
(2.98) log10 lower, and serum HBV DNA levels 4.00 (4.50)
log10 lower in HBeAg-negative as compared with HBeAg-
positive patients. These differences influence the ratios
Fig. 1 Correlations between intrahepatic HBV DNA (ihDNA) cccDNA, pregenomic RNA (pgRNA) and serum HBV DNA within HBeAg-positive patients.
pgRNA vs. cccDNA (a), ihDNA vs. pgRNA (b), HBV DNA vs. ihDNA (c), and HBV DNA vs. pgRNA (d). All values are log10 copies/cell equivalent (cEq) if not
stated otherwise
Fig. 2 Correlations between intrahepatic HBV DNA (ihDNA), cccDNA, pregenomic RNA (pgRNA) and serum HBV DNA within HBeAg-negative patients.
pgRNA vs. cccDNA (a), ihDNA vs pgRNA (b), and HBV DNA vs. ihDNA (c). All values are log10 copies/cell equivalent (cEq) if not stated otherwise
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between these parameters as shown in Fig. 3b. Thus,
the HBV DNA/pgRNA and HBV DNA/ihDNA ratios
were much lower, whereas the HBsAg/S-RNA ratio was
the same, in HBeAg-negative as compared with HBeAg-
positive patients.
Difference in reduction of viral and subviral particles
This was studied by comparing HBV DNA and HBsAg
levels in serum (i.e. the ratio between them), and by
comparing the corresponding transcripts (pgRNA and
S-RNA). As shown in Fig. 3a, the levels of HBsAg and
Fig. 3 Box plots of serum and intrahepatic levels of hepatitis B virus markers in HBeAg-positive and HBeAg-negative patients (a) and their ratios
(b and c). Each box shows median and 25th and 75th percentile, the bars 10th and 90th percentile, and open circles results outside the latter range.
cEq, cell equivalent
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S-RNA were only moderately lower in HBeAg-negative
patients (mean 1.0, median 0.87 log10 for HBsAg; mean
1.24, median 1.72 log10 for S-RNA). The diverging de-
gree of reduction of viral and subviral particles is fur-
ther illustrated by Fig. 3c, which shows how ratios
between levels of viral and subviral markers change after
loss of HBeAg. Thus, there was a marked reduction of
the HBV DNA/HBsAg ratio, and this was to some ex-
tent observed also for the corresponding transcripts,
pgRNA/S-RNA. However, whereas the ratio pgRNA/
cccDNA was lower after loss of HBeAg, the ratio S-
RNA/cccDNA was instead increased. Thus, the pgRNA/
cccDNA ratio was significantly lower than S-RNA/cccDNA
in HBeAg-negative patients (P < 0.0001), but similar in
HBeAg-positive patients.
Discussion
This study of intrahepatic HBV RNA and HBV DNA
and their correlation with each other and with levels
of HBV DNA and HBsAg in serum may help to
understand how HBV replication is suppressed during
the course of infection and how low serum levels of
HBV DNA and HBsAg are achieved. Part of our re-
sults agree well with published studies [11–13], but
the observations of an increased S-RNA/pgRNA ratio
after loss of HBeAg, and of the much greater decline
of serum HBV DNA than of intrahepatic HBV DNA
have to our knowledge not been described before.
Within HBeAg-positive patients, lower serum levels of
HBV DNA essentially reflected lower levels of the
cccDNA template in combination with reduced amounts
of pgRNA per cccDNA. Our results, with a 2 log10 lower
cccDNA level in HBeAg-negative patients are identical
with the observations by Werle-Lapostelle et al. [11],
whereas other studies have reported smaller reduction
(≈1 log10) after loss of HBeAg [12, 13]. The reduced
levels of cccDNA after loss of HBeAg is probably mainly
a result of eradication of infected hepatocytes by cyto-
toxic T cells [14] in combination with lower cccDNA
content in each infected cell.
Concern has been raised regarding the specificity of
cccDNA PCR assay, i.e. whether this assay amplifies only
cccDNA. When this method was introduced by Köck
and Schlicht they showed that the degree of cross-
reactivity, i.e. amplification by cccDNA primers of other
forms of HBV DNA, was low, corresponding to a 3 log10
lower sensitivity [15]. We found the same degree of
cross-reactivity when we repeated their experiments
using real-time PCR (results not shown). When analys-
ing liver biopsies, we found that cccDNA levels were on
average 1.90 log10 lower than ihDNA, and not 3 log10
lower as one would expect if the cccDNA findings were
due to cross-reactivity. This indicates that a low
specificity of the assay should have limited impact on
our cccDNA results.
In addition to lower cccDNA levels, we found in HBeAg-
negative patients a lower pgRNA/cccDNA ratio. This
mechanism of reduced virus production has been pro-
posed by others, and might be mediated by different
mechanisms such as accelerated intracellular clearance
of pgRNA-containing capsids induced by IFN-alfa/-beta
[16], or by IFN-alfa mediated suppression of HBV repli-
cation by epigenetic control of cccDNA function and
transcription [17]. Among our patients, the reduction
of the pgRNA/cccDNA ratio was quite moderate (0.57
log10), whereas Volz et al. and Laras et al. found larger
reductions (0.88 and 1.46 log10) [12, 13].
Within HBeAg-positive stage, pgRNA and serum HBV
DNA correlated strongly with a slope of ≈ 1, meaning
that 1 log10 decline of pgRNA results in 1 log10 decline
of HBV DNA in serum. In HBeAg-negative patients,
the relations between cccDNA, replicative intermediates
(pgRNA and ihDNA) and levels of HBV DNA in serum
were more complex.
Firstly, levels of pgRNA showed poorer correlation with
cccDNA, suggesting that suppression acting on this step
varies considerably between patients.
Secondly, in patients with lower cccDNA there were
relatively higher levels of ihDNA, as indicated by both
the slope of the ihDNA/pgRNA regression line and the
higher ihDNA/pgRNA ratio in HBeAg-negative patients.
The explanation to this relative increase of ihDNA among
HBeAg-negative patients is uncertain. It might be due to
production of non-productive replicative intermediates, or
retention of viral particles that are not secreted into the
blood. The latter possibility would agree with a study de-
scribing that viral particles can be blocked by anti-HBs
antibodies internalized in liver cells [18]. Another study
did however not report differences in virion release be-
tween HBeAg-positive and negative patients [19], and our
finding and possible explanations need to be further ex-
plored. One also has to consider the possibility that inte-
grated HBV DNA contributes to ihDNA, because such
integrations would be detected by our real-time PCR as-
says (if they include the target region). In early stage their
contribution would probably be minimal, but when the
production of relaxed circular DNA in virions declines in
HBeAg-negative patients the amount of integrated HBV
DNA might be high enough to influence the measured
ihDNA level.
Thirdly, in several HBeAg-negative patients the HBV
DNA level in serum was reduced much more than what
would be expected by the reduction of ihDNA, suggesting
that factors acting downstream of reverse transcription
may have great impact on HBV DNA in serum. Such fac-
tors might, as mentioned above, be reduced release of vi-
rions from infected cells, or shorter half-life of viral
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particles in serum. The possibility that enhanced clearance
of free virions from the blood contributes to the pro-
nounced reduction of HBV DNA levels in serum after loss
of HBeAg has not been much studied or discussed. Math-
ematical calculations based on HBV kinetics under anti-
viral therapy [20] suggested that the half-life of free
virions is ~25 h in HBeAg-positive and ~13 h in
HBeAg-negative patients [21]. Another study reported
similar half-lives in HBeAg-positive patients (17 h), but
extremely short half-life in HBeAg-negative patients
(0.6 s) [19], data that subsequently were questioned [22].
Despite the discrepancies it seems likely that stronger im-
munologic responses may lead to faster clearance of vi-
rions, but how much this influences serum levels of HBV
DNA remains to be elucidated.
Whereas HBV DNA levels were more than 4.0 log10
lower in HBeAg-negative patients, levels of HBsAg were
on average only 1.1 log10 lower. Accordingly, the HBV
DNA/HBsAg ratio was 3.3 log10 lower in HBeAg-negative
patients, as observed also in previous studies [13, 23, 24].
To some extent this was explained by a reduced ratio (by
2.0 log10) between the corresponding transcripts (pgRNA/
S-RNA) in HBeAg-negative patients. This reduction of
pgRNA/S-RNA is greater than the 1.2 log10 difference re-
ported by Volz et al. [13], and was explained by both re-
duced pgRNA/cccDNA (as mentioned above) and an
increased S-RNA/cccDNA ratio by 1.0 log10. This finding
suggests that the smaller reduction of HBsAg after loss of
HBeAg than expected from the cccDNA decline might
be due to an enhanced transcription of S-RNA from
cccDNA, or possibly transcription of S-RNA from inte-
grated sequences of HBV DNA that contain the complete
S region, including the promoter. Such transcription oc-
curs in the Alexander hepatoma cell line [25], but whether
this type of integrations occur during natural infection re-
mains to be demonstrated.
The ratio between HBsAg/S-RNA was unchanged
after loss of HBeAg, indicating that post-transcriptional
processing of S-RNA and turnover of subviral particles
remain unchanged after loss of HBeAg.
Conclusions
Figure 4 summarises the main findings in this study,
pointing out three novel observations for HBeAg-negative
patients:
i. A much lower HBV DNA/ihDNA ratio shows that
mechanisms downstream of reverse transcription or
downstream of secretion of virions strongly
influence HBV DNA levels in serum.
ii. An unchanged HBsAg/S-RNA ratio suggests that
secretion and degradation of SVP do not change
after loss of HBeAg.
iii. An increased S-RNA/cccDNA ratio suggests that




From a cross-sectional study of 160 patients with chronic
HBV infection focusing on histology and HBV DNA levels
[26] a total of 84 patients were included in this study, 16
positive and 68 negative for HBeAg. The present study is
an extension of a previous study by our group [3]. From
these patients liver biopsies were available for analysis
by molecular techniques. None of the patients were co-
infected with hepatitis C or D viruses, or HIV. The pa-
tients represented different genotypes and phases of HBV
Fig. 4 Flowchart showing differences in intrahepatic and serum viral load between HBeAg-positive and HBeAg-negative patients.Δe indicates
mean difference between levels in HBeAg-positive and HBeAg-negative patients. Three novel findings are pointed out: (i) a greater reduction of
HBV DNA in serum as compared with in the liver; (ii) an unchanged HBsAg/S RNA ratio; (iii) an increased S-RNA/cccDNA ratio, in HBeAg-negative
as compared with HBeAg-positive patients
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infection. Serum samples that were used for quantification
of HBV DNA and HBsAg were taken at the time of
biopsy. All patients gave informed consent and The
Regional Ethical Review Board in Gothenburg approved
the study.
Laboratory assessments
Serum HBV DNA was analysed by Cobas Amplicor HBV
Monitor (Roche Diagnostic Systems, Branchburg, NJ) and
HBsAg in serum was quantified using the Architect assay
(Abbott, Abbott Park, IL).
Portions (approximately 5 mg) of liver biopsies were
investigated. The liver biopsies were stored in –70 °C
until analysed. After homogenization of the liver tissue
in a MagNA Lyser instrument (Roche Diagnostics), ex-
traction of nucleic acids was performed in the MagNA
Pure (Roche) robot according to the manufacturer’s
protocol, using the DNA II Tissue kit.
Real-time PCR was performed using primers specific
for cccDNA as previously described [3]. These primers
amplify a segment spanning the gaps in the plus and
minus strands of the relaxed circular form of the genome
that is present in viral particles. Levels of cccDNA were
normalised to the concentration of human betaglobin
DNA. Total intrahepatic HBV DNA was analysed by the
same primers as for pgRNA but without the reverse tran-
scription step. Part of the extracted NAs was treated with
DNase (Ambion Inc.), and S-RNA and pgRNA transcripts
were quantified by real-time PCR after a reverse transcrip-
tion step (details of the primers are shown in Table 2).
Due to the overlap of S and pgRNA transcripts, the S
primers and probe also detects pgRNA. Normalization of
RNA levels was made using 18S RNA as reference.
Statistical analysis
Differences in levels of HBV RNA or DNA between
groups were analysed by unpaired t-test. Correlations
were made by linear regression and Pearson’s correlation
analysis. P values below 0.05 were considered significant.
The Statview software (SAS Institute) was used for stat-
istical analyses.
Abbreviations
cccDNA: covalently closed circular DNA; HBeAg: hepatitis B e antigen;
HBsAg: hepatitis B surface antigen; HBV: hepatitis B virus; ihDNA: intrahepatic
DNA; pgRNA: pregenomic RNA.
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